Reported Earlier, MediciNova Receives U.S. Patent Allowance For MN-166, Ensuring Broad Protection For Post-COVID Treatment Through 2042
Reported Earlier, MediciNova Receives U.S. Patent Allowance For MN-166, Ensuring Broad Protection For Post-COVID Treatment Through 2042
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers MN-166 (ibudilast) for post-COVID conditions. The Method of Use patent covers administering a therapeutically effective doses of ibudilast (or a pharmaceutically acceptable salt thereof) to alleviate a range of post-COVID conditions including anxiety, fatigue, depression, shortness of breath, post-traumatic stress disorder, chest tightness, palpitations, smell or taste dysfunction, sleep difficulties, hair loss, and rash.
位於納斯達克全球市場（NASDAQ:MNOV）和東京證券交易所標準市場（代碼：4875）上市的生物製藥公司MediciNova, Inc.宣佈，其一項待審專利申請已經獲得美國專利和商標局的批准通知，該專利涵蓋了ibudilast（即MN-166）用於新冠後症狀的方法。該使用方法專利涵蓋了以治療有效劑量的ibudilast（或其藥學可接受的鹽）來緩解一系列新冠後症狀，包括焦慮、疲勞、抑鬱、呼吸困難、創傷後壓力障礙、胸悶、心悸、嗅覺或味覺障礙、睡眠困難、脫髮和皮疹。
譯文內容由第三人軟體翻譯。